Skip to content

SPIN PHARMA — home

Evidence, labelled
Breakthroughs
Significant discoveries, therapy advances and trial results — with every early-stage finding clearly labelled for what it is.
Open Breakthroughs
Latest storyA Drug That Works in Cells Isn’t a Cure: How to Read a Biotech Breakthrough
Algorithms meet the clinic
AI + Medicine
Drug discovery, diagnostics, AI-assisted MRI and imaging, clinical trials, robotics, wearables and hospital workflows.
Open AI + Medicine
Latest storyCan AI Spot Cancer Earlier? Where Imaging Helps and Where False Alarms Matter
Science ≠ share price
Companies + Stocks
Public companies and startups, pipelines, partnerships, funding and milestones — scientific progress kept separate from market performance.
Open Companies + Stocks
Latest storyThe Biotech Startup Map: How Young Companies Move From Discovery to Patients
Hardware for health
DeepTech + MedTech
Imaging, surgical technology, sensors, lab automation, organoids, bioprinting, brain health and next-generation devices.
Open DeepTech + MedTech
Latest storyThe MRI Reinvention: Faster Scans, Better Images, and the Real Role of AI
Read, write, edit
Genome + Cells
Sequencing, gene editing, gene therapy, epigenetics, cell therapies — and what genomic data can and cannot tell us.
Open Genome + Cells
Latest storyDecode the Genome: What Sequencing Can Tell Us—and What It Cannot
Many diseases, many answers
Cancer Frontiers
Treatments by mechanism, early detection, precision oncology, immunotherapy and prevention research. Cancer is many diseases — we report it that way.
Open Cancer Frontiers
Latest storyIs There a Cure for Cancer? The Better Question Is: Which Cancer, at What Stage, and With Which Treatment?
Healthspan, honestly
Longevity
Aging biology, healthspan, clinical evidence and interventions under study — with an honest line between hype and evidence.
Open Longevity
Latest storyThe Cell Health Frontier: Senescence, Mitochondria, and the Search for Better Healthspan
Explore
The Lab
Thoughtful “What if?” experiments. Speculation is always labelled — and polls are never evidence.
Open The Lab
FeaturedWhat if an MRI scan took a fraction of the time?
Explore
Play + Learn
Educational games, quizzes, visual explainers and videos.
Open Play + Learn
FeaturedDrug Development Journey
Explore
Resources
Universities, research institutions, journals, public databases, trials and a glossary — plus who we are.
Open Resources

Get The Spin Brief About Spin Pharma

Get The Spin Brief

Search

CRISPR MRI immunotherapy clinical trial organoids biological age

Home
NewLimit

Company mentioned

NewLimit

NEPrivate startup

NewLimit

Not publicly traded

NewLimit develops epigenetic reprogramming medicines intended to restore youthful function to aged cells, starting with liver cells. It was co-founded by Brian…

Most advanced: PreclinicalVerified Sep 2026

SPIN PHARMA — home

See what’s next in health. Evidence-first reporting on biotech, AI, genomics, medtech, cancer research and longevity.

The Spin Brief — weekly, concise, evidence-first.

Email address

I agree to receive The Spin Brief by email and accept the privacy policy. Unsubscribe any time with one click.

Leave this empty

Sections

Breakthroughs
AI + Medicine
Companies + Stocks
DeepTech + MedTech
Genome + Cells
Cancer Frontiers
Longevity

Learn & explore

The Lab
Play + Learn
Videos
Pipeline tracker
Company directory
Resources
Glossary
Explore & filter

Spin Pharma

About Spin Pharma
Editorial standards
Disclosures & sponsorship
The Spin Brief newsletter
Contact
Privacy & consent
Our network

Not medical or investment advice. Spin Pharma publishes general education and journalism. It does not diagnose, recommend treatments or recommend securities. Talk to a qualified clinician about your health, and a licensed adviser about investments. Company profiles and watchlists are informational.

© 2026 Spin Pharma · A Mass Density, Inc. publication · Illustrations are original artwork and do not depict real patients, scans or trial results.